Literature DB >> 22948045

How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing.

Nelson Leung1, Samih H Nasr, Sanjeev Sethi.   

Abstract

Amyloidosis is a rare group of diseases characterized by deposition of amyloid fibrils in soft tissues. More than 28 types of amyloid have been identified. They all share common ultrastructural and chemical characteristics. Treatments are available for many types but are type specific. Therefore, confirmation and typing of amyloid are essential before initiating treatment. Monoclonal protein studies should be performed on suspected cases, but the diagnosis requires a tissue biopsy. Congo red stain and electron microscopy are helpful to discriminate between amyloid and other pathologic fibrils. Once amyloid is confirmed, typing should be performed. Immunofluorescence and immunohistochemistry are frequently used and are helpful, but this approach has limitations, such as availability, specificity and sensitivity of commercial antibodies. Genetic mutational analysis is vital for ruling in and out hereditary amyloidoses but is unhelpful in nonmutated forms. The most advanced technique of amyloid typing is laser microdissection followed by mass spectrometry. Using proteomics, laser microdissection followed by mass spectrometry can directly identify proteins with or without mutations. Finally, imaging studies, such as cardiac MRI with gadolinium and (123)I-labeled SAP scintigraphy not only assist in evaluation of patients with known amyloidosis but cardiac MRI has detected amyloid in patients previously unsuspected of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948045     DOI: 10.1182/blood-2012-03-413682

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition.

Authors:  Neha Mehta; Heiko Schöder; April Chiu; John Kenneth Schoolmeester; Carol Portlock
Journal:  BMJ Case Rep       Date:  2014-11-14

Review 2.  The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Authors:  Sanjeev Sethi; S Vincent Rajkumar; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2018-04-27       Impact factor: 10.121

3.  Imaging mass spectrometry: a new tool for pathology in a molecular age.

Authors:  Jeremy L Norris; Richard M Caprioli
Journal:  Proteomics Clin Appl       Date:  2013-12       Impact factor: 3.494

4.  Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry.

Authors:  Kanji Miyazaki; Shigeo Kawai; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2015-06-27       Impact factor: 2.490

5.  Amyloidosis: The Newer Discovered ALECT2 Associated with der7q add(7).

Authors:  Amrita Chakrabarti; Priyanka Samal; Joydeep Chakrabartty
Journal:  J Clin Diagn Res       Date:  2016-09-01

6.  Primary Systemic Amyloidosis Involving the Lacrimal Sac.

Authors:  Joseph Kim; Lucia Kim; Sung Mo Kang
Journal:  Korean J Ophthalmol       Date:  2016-05-18

Review 7.  Approach to the Diagnosis of Amyloidosis.

Authors:  Richa Juneja; H P Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-09       Impact factor: 0.900

Review 8.  Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury?

Authors:  Mona Doshi; Amit Lahoti; Farhad R Danesh; Vecihi Batuman; Paul W Sanders
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

Review 9.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

Review 10.  Dysproteinemias and Glomerular Disease.

Authors:  Nelson Leung; Maria E Drosou; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.